vs
优尼威（CLMB）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
优尼威的季度营收约是Vericel Corp的2.0倍（$182.4M vs $92.9M），Vericel Corp净利率更高（25.0% vs 1.8%，领先23.2%），优尼威同比增速更快（32.1% vs 23.3%），过去两年优尼威的营收复合增速更高（40.7% vs 34.6%）
优尼威解决方案是一家全球化学品与原料分销商，同时可为客户提供各类增值服务，在行业内拥有广泛的全球布局与专业服务能力。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
CLMB vs VCEL — 直观对比
营收规模更大
CLMB
是对方的2.0倍
$92.9M
营收增速更快
CLMB
高出8.8%
23.3%
净利率更高
VCEL
高出23.2%
1.8%
两年增速更快
CLMB
近两年复合增速
34.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $182.4M | $92.9M |
| 净利润 | $3.3M | $23.2M |
| 毛利率 | 14.5% | 78.7% |
| 营业利润率 | 2.1% | 24.1% |
| 净利率 | 1.8% | 25.0% |
| 营收同比 | 32.1% | 23.3% |
| 净利润同比 | -9.5% | 17.3% |
| 每股收益（稀释后） | $0.18 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLMBVCEL
| Q1 26 | $182.4M | — | ||
| Q4 25 | $193.8M | $92.9M | ||
| Q3 25 | $161.3M | $67.5M | ||
| Q2 25 | $159.3M | $63.2M | ||
| Q1 25 | $138.0M | $52.6M | ||
| Q4 24 | $161.8M | $75.4M | ||
| Q3 24 | $119.3M | $57.9M | ||
| Q2 24 | $92.1M | $52.7M |
净利润CLMBVCEL
| Q1 26 | $3.3M | — | ||
| Q4 25 | $7.0M | $23.2M | ||
| Q3 25 | $4.7M | $5.1M | ||
| Q2 25 | $6.0M | $-553.0K | ||
| Q1 25 | $3.7M | $-11.2M | ||
| Q4 24 | $7.0M | $19.8M | ||
| Q3 24 | $5.5M | $-901.0K | ||
| Q2 24 | $3.4M | $-4.7M |
毛利率CLMBVCEL
| Q1 26 | 14.5% | — | ||
| Q4 25 | 15.4% | 78.7% | ||
| Q3 25 | 15.9% | 73.5% | ||
| Q2 25 | 16.5% | 73.7% | ||
| Q1 25 | 16.9% | 69.0% | ||
| Q4 24 | 19.3% | 77.6% | ||
| Q3 24 | 20.3% | 71.9% | ||
| Q2 24 | 20.2% | 69.5% |
营业利润率CLMBVCEL
| Q1 26 | 2.1% | — | ||
| Q4 25 | 4.9% | 24.1% | ||
| Q3 25 | 4.3% | 5.1% | ||
| Q2 25 | 5.0% | -3.2% | ||
| Q1 25 | 3.5% | -24.3% | ||
| Q4 24 | 7.2% | 24.5% | ||
| Q3 24 | 7.1% | -4.3% | ||
| Q2 24 | 4.6% | -11.5% |
净利率CLMBVCEL
| Q1 26 | 1.8% | — | ||
| Q4 25 | 3.6% | 25.0% | ||
| Q3 25 | 2.9% | 7.5% | ||
| Q2 25 | 3.7% | -0.9% | ||
| Q1 25 | 2.7% | -21.4% | ||
| Q4 24 | 4.3% | 26.3% | ||
| Q3 24 | 4.6% | -1.6% | ||
| Q2 24 | 3.7% | -8.9% |
每股收益（稀释后）CLMBVCEL
| Q1 26 | $0.18 | — | ||
| Q4 25 | $1.51 | $0.46 | ||
| Q3 25 | $1.02 | $0.10 | ||
| Q2 25 | $1.30 | $-0.01 | ||
| Q1 25 | $0.81 | $-0.23 | ||
| Q4 24 | $1.52 | $0.40 | ||
| Q3 24 | $1.19 | $-0.02 | ||
| Q2 24 | $0.75 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $41.8M | $137.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $118.4M | $354.6M |
| 总资产 | $458.8M | $488.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLMBVCEL
| Q1 26 | $41.8M | — | ||
| Q4 25 | $36.6M | $137.5M | ||
| Q3 25 | $49.8M | $135.4M | ||
| Q2 25 | $28.6M | $116.9M | ||
| Q1 25 | $32.5M | $112.9M | ||
| Q4 24 | $29.8M | $116.2M | ||
| Q3 24 | $22.1M | $101.7M | ||
| Q2 24 | $48.4M | $102.5M |
股东权益CLMBVCEL
| Q1 26 | $118.4M | — | ||
| Q4 25 | $116.6M | $354.6M | ||
| Q3 25 | $109.3M | $321.9M | ||
| Q2 25 | $105.2M | $306.8M | ||
| Q1 25 | $95.6M | $295.5M | ||
| Q4 24 | $90.6M | $292.0M | ||
| Q3 24 | $87.7M | $257.5M | ||
| Q2 24 | $79.8M | $243.0M |
总资产CLMBVCEL
| Q1 26 | $458.8M | — | ||
| Q4 25 | $460.2M | $488.0M | ||
| Q3 25 | $376.1M | $453.3M | ||
| Q2 25 | $420.7M | $435.6M | ||
| Q1 25 | $370.1M | $424.6M | ||
| Q4 24 | $469.2M | $432.7M | ||
| Q3 24 | $371.9M | $390.4M | ||
| Q2 24 | $302.8M | $376.8M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $15.0M |
| 自由现金流经营现金流 - 资本支出 | — | $12.8M |
| 自由现金流率自由现金流/营收 | — | 13.8% |
| 资本支出强度资本支出/营收 | — | 2.4% |
| 现金转化率经营现金流/净利润 | — | 0.65× |
| 过去12个月自由现金流最近4个季度 | — | $24.7M |
8季度趋势，按日历期对齐
经营现金流CLMBVCEL
| Q1 26 | — | — | ||
| Q4 25 | $-11.9M | $15.0M | ||
| Q3 25 | $22.2M | $22.1M | ||
| Q2 25 | $-2.2M | $8.2M | ||
| Q1 25 | $8.5M | $6.6M | ||
| Q4 24 | $16.0M | $22.2M | ||
| Q3 24 | $-3.6M | $10.2M | ||
| Q2 24 | $7.3M | $18.5M |
自由现金流CLMBVCEL
| Q1 26 | — | — | ||
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M |
自由现金流率CLMBVCEL
| Q1 26 | — | — | ||
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% |
资本支出强度CLMBVCEL
| Q1 26 | — | — | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% |
现金转化率CLMBVCEL
| Q1 26 | — | — | ||
| Q4 25 | -1.70× | 0.65× | ||
| Q3 25 | 4.73× | 4.35× | ||
| Q2 25 | -0.37× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 2.29× | 1.12× | ||
| Q3 24 | -0.66× | — | ||
| Q2 24 | 2.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLMB
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
